Contineum Therapeutics (CTNM) Research & Development (2023 - 2026)

Contineum Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 15.05% year-over-year to $11.6 million in Q1 2026; TTM through Mar 2026 was $49.5 million, a 11.5% increase from a year earlier, with the FY2025 full-year figure at $51.5 million, up 34.1% from the prior year.
• Research & Development fell to $11.6 million in Q1 2026 per CTNM's latest filing, from $12.8 million in the prior quarter.
• Across five years, Research & Development topped out at $14.1 million in Q2 2025 and bottomed at $3.6 million in Q1 2023.
• The 4-year median for Research & Development is $9.7 million (2024), against an average of $9.9 million.
• Biggest YoY gain for Research & Development was 114.15% in 2024; the steepest drop was 16.48% in 2024.
• Year by year, Research & Development stood at $8.0 million in 2023, then soared by 62.44% to $13.0 million in 2024, then fell by 2.0% to $12.8 million in 2025, then dropped by 8.68% to $11.6 million in 2026.
• Per Business Quant, the three latest CTNM Research & Development figures stand at $11.6 million (Q1 2026), $12.8 million (Q4 2025), and $11.0 million (Q3 2025).